261
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
Condition(s):CancerLast Updated:March 26, 2012Withdrawn
Refractory Multiple Myeloma: 1469 Clinical Trials, Page 27 of 147
Hide Studies Not Open or Pending
262
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 4, 2022Completed
263
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 15, 2023Recruiting
264
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:January 7, 2013Completed
265
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:November 12, 2019Unknown status
266
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 16, 2023Active, not recruiting
267
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:December 21, 2021Completed
268
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:January 17, 2023Active, not recruiting
269
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 26, 2023Recruiting
270
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:February 1, 2023Recruiting